source
- GSK allocates over $800 million to expand R&D and manufacturing hub in PennsylvaniaGSK announced it will invest more than $800 million to expand its presence in Pennsylvania, marking its second expansion in the state within two years. The funds will be used to build a new resear…
- RevMed's pancreatic cancer drug Rasonque shows mixed results across KRAS subtypes, analysts stay optimisticFDA review documents revealed that Revolution Medicines' newly approved pancreatic cancer therapy, Rasonque, performed unevenly in a large subgroup of patients. The data highlight a lower objective…